While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Ends Supply of AstraZeneca’s COVID Jab, 13.5 Million Doses Discarded
October 3, 2022
-
REGULATORY Wholesalers Question Inflexibility in Official Pricing, Sees Limit to Addressing Rising Costs
September 30, 2022
-
BUSINESS Ferring Japan CEO Confident of Growth in Fertility Drugs Spurred by Rising Demand on Health Coverage
September 30, 2022
-
BUSINESS Lecanemab Hits PIII Mark with 27% Cut in Clinical Decline, Eisai Set for Submissions by March-End
September 29, 2022
-
ORGANIZATION Policy Veterans’ Group Proposes Simple Drug Price Maintenance Scheme for Patented Meds
September 28, 2022
-
REGULATORY Japan Approves Mounjaro, Tezspire, Fintepla, Label Expansions for Rinvoq/Skyrizi, Keytruda, and More
September 27, 2022
-
BUSINESS Ivermectin Misses Goal in PIII COVID-19 Trial: Kowa
September 27, 2022
-
REGULATORY Revamped Expert Panel Holds Industry Hearing, Discussions Center on Drug Price Gap
September 26, 2022
-
BUSINESS Janssen Aims to Rank Among Top 3 Drug Makers in Japan by 2024: Local Chief
September 22, 2022
-
REGULATORY 2 Years after Full Rollout, Sakigake System Shows Tepid Uptake as Industry Sees Poor Incentives
September 21, 2022
-
REGULATORY Japan Launches Omicron Booster Program for COVID-19
September 21, 2022
-
REGULATORY MHLW Retools New Expert Panel, Industry Hearing Set for Sept. 22
September 21, 2022
-
BUSINESS Boehringer Ingelheim Revamping Biz Sites in Japan to Spur Communications among Drug Reps
September 20, 2022
-
BUSINESS Insmed CEO Sees Japan as Cornerstone of APAC Strategy, Doubling of Staff in Next 2 Years
September 16, 2022
-
BUSINESS Moderna to Have One of Industry’s Biggest Pipelines in 5 Years, Oncology Might Make Up 30% of Sales: CEO
September 15, 2022
-
BUSINESS Alnylam Japan Paints Two-Digit Annual Growth Outlook on ATTR Meds and Pipeline Drugs
September 14, 2022
-
BUSINESS Pfizer Seeks Japan Nod for BA.4/5-Adapted COVID-19 Vaccine
September 13, 2022
-
REGULATORY Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
September 13, 2022
-
COMMENTARY Delving into Potential Implications of Envisaged Price Revision Overhaul
September 12, 2022
-
ORGANIZATION FPMAJ-Eyed Overhaul of Price Revision Rules Likely to Curb Price Falls, Cover JP-Listed Meds, Essential Drugs and More
September 9, 2022
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…